Junshi's PD-1 Candidate Approved for US Fast Track Review

Junshi Bio of Shanghai was granted US Fast Track status by the FDA for its anti-PD-1, toripalimab, to treat patients with advanced mucosal melanoma. The drug will be administered together with axitinib, a Pfizer VEGFR inhibitor, in a Phase III trial. In 2018, toripalimab was the first China-developed PD-1 therapy to be approved in China . The first approval was for second-line treatment of metastatic melanoma. Junshi is conducting more than thirty clinical trials of toripalimab globally for 15 indications. More details.... Stock Symbols: (HK: 1877; SHA: 688180) Share this with colleagues: // //